Bayer Hopeful Of Sweet Success With KaNDy Buy
Gets Hold Of Late-Stage Non-Hormonal Menopause Drug
Bayer is paying $425m upfront to acquire KaNDy Therapeutics, whose CEO tells Scrip that the German group was always the preferred partner due to its long-standing commitment to women’s health.
